Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder

Acta Paediatrica, International Journal of Paediatrics

Volumn 100, Issue 9, 2011, Pages 1258-1261

  Zeiner, Pål ^a   Gjevik, Elen ^a   Weidle, Bernhard ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Autism spectrum disorders; Drug response

Indexed keywords

ATOMOXETINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL GLOBAL IMPROVEMENT SCALE; CLINICAL TRIAL; COMORBIDITY; COMPULSION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; IRRITABILITY; MALE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; STOMACH PAIN; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HEALTH STATUS INDICATORS; HUMANS; MALE; NORWAY; OUTPATIENTS; PROPYLAMINES; PROSPECTIVE STUDIES; PSYCHOMETRICS; SEX FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 80051878678     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2011.02263.x     Document Type: Article

References (17)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Text revision. (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
2. Gjevik E, Eldevik S, Fjæran-Granum T, Sponheim E,. Kiddie-SADS reveals high rates of DSM-IV disorders in children and adolescents with autism spectrum disorders. J Autism Dev Disord 2010; Sep 8 [Epub ahead of print].
3. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G,. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 2008; 47: 921-9.
4. Mattila ML, Hurtig T, Haapsamo H, Jussila K, Kuusikko-Gauffin S, Kielinen M, et al., Comorbid psychiatric disorders associated with Asperger syndrome/high-functioning autism: a community- and clinic-based study. J Autism Dev Disord 2010; 40: 1080-93.
5. Aman MG, Farmer CA, Hollway J, Arnold LE,. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatry Clin N Am 2008; 17: 713-38.
6. Research Units on Pediatric Psychopharmacology Autism Network. A randomized double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Arch Gen Psychiatry 2005; 62: 1266-74.
7. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL,. Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2008; 2: 25.
8. Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, et al., Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006; 45: 1196-205. (Pubitemid 44465640)
9. Jou RJ, Handen BL, Hardan AY,. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15: 325-30. (Pubitemid 40734112)
10. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ,. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16: 599-610. (Pubitemid 44739916)
11. Troost PW, Steenhuis MP, Tuynman-Qua HG, Kalverdijk LJ, Buitelaar JK, Minderaa RB, et al., Atomoxetine for attention deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006; 16: 611-9. (Pubitemid 44737214)
12. Charnsil C,. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study. J Atten Disord 2010; 4 [Epub ahead of print].
13. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al., Schedule for affective disorders and Schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-8. (Pubitemid 27272932)
14. Zhang S, Faries DE, Vowles M, Michelson D,. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res 2005; 14: 186-201. (Pubitemid 43013586)
15. Goodman R,. The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry 1997; 38: 581-6. (Pubitemid 27341892)
16. SPSS for Windows version 16.0. Chicago: SPSS Inc., 2008.
17. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al., Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165: 721-30. Epub. (Pubitemid 351810541)